These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28220299)

  • 41. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
    Charles J; Beani JC; Fiandrino G; Busser B
    J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
    [No Abstract]   [Full Text] [Related]  

  • 42. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
    Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
    J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.
    Feng S; Han L; Yue M; Zhong D; Cao J; Guo Y; Sun Y; Zhang H; Cao Z; Cui X; Liu R
    Orphanet J Rare Dis; 2021 Jun; 16(1):272. PubMed ID: 34116682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Langerhans cell histiocytosis of the stomach with BRAF-V600E-mutation: case report and review of the literature].
    Sarbia M; Mauerer R; Bettstetter M; Funk A
    Z Gastroenterol; 2015 Apr; 53(4):302-5. PubMed ID: 25860580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
    Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
    J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
    Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidental Langerhans cell histiocytosis of the colon with
    Cortazar JM; Kim AS
    Blood; 2017 Oct; 130(16):1870. PubMed ID: 29051154
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical Spectrum, Quality of Life, BRAF Mutation Status and Treatment of Skin Involvement in Adult Langerhans Cell Histiocytosis.
    Crickx E; Bouaziz JD; Lorillon G; de Menthon M; Cordoliani F; Bugnet E; Bagot M; Rybojad M; Mourah S; Tazi A
    Acta Derm Venereol; 2017 Jul; 97(7):838-842. PubMed ID: 28421232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
    Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
    Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis.
    Rowe LR; Bentz BG; Bentz JS
    J Clin Pathol; 2007 Nov; 60(11):1211-5. PubMed ID: 17298986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules.
    Yeo MK; Liang ZL; Oh T; Moon Y; An S; Kim MK; Kim KS; Shong M; Kim JM; Jo YS
    Clin Endocrinol (Oxf); 2011 Oct; 75(4):555-60. PubMed ID: 21609347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
    Anderson S; Bloom KJ; Vallera DU; Rueschoff J; Meldrum C; Schilling R; Kovach B; Lee JR; Ochoa P; Langland R; Halait H; Lawrence HJ; Dugan MC
    Arch Pathol Lab Med; 2012 Nov; 136(11):1385-91. PubMed ID: 22332713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas.
    Jo YS; Huang S; Kim YJ; Lee IS; Kim SS; Kim JR; Oh T; Moon Y; An S; Ro HK; Kim JM; Shong M
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):139-44. PubMed ID: 18462259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.